VELTASSA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Veltassa, and when can generic versions of Veltassa launch?
Veltassa is a drug marketed by Vifor Pharma and is included in one NDA. There are thirteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and eighty-five patent family members in twenty-six countries.
The generic ingredient in VELTASSA is patiromer sorbitex calcium. One supplier is listed for this compound. Additional details are available on the patiromer sorbitex calcium profile page.
DrugPatentWatch® Generic Entry Outlook for Veltassa
Veltassa was eligible for patent challenges on October 21, 2019.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 29, 2030. This may change due to patent challenges or generic licensing.
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for VELTASSA
International Patents: | 185 |
US Patents: | 13 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 13 |
Drug Prices: | Drug price information for VELTASSA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VELTASSA |
What excipients (inactive ingredients) are in VELTASSA? | VELTASSA excipients list |
DailyMed Link: | VELTASSA at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for VELTASSA
Generic Entry Date for VELTASSA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VELTASSA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of California, Irvine | Phase 4 |
University of Glasgow | Phase 4 |
NHS Greater Glasgow and Clyde | Phase 4 |
Pharmacology for VELTASSA
Drug Class | Potassium Binder |
Mechanism of Action | Potassium Ion Binding Activity |
Paragraph IV (Patent) Challenges for VELTASSA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VELTASSA | for Oral Suspension | patiromer sorbitex calcium | 8.4 g, 16.8 g and 25.2 g | 205739 | 2 | 2019-10-21 |
US Patents and Regulatory Information for VELTASSA
VELTASSA is protected by thirteen US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VELTASSA is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VELTASSA
Ion binding polymers and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERKALEMIA
Potassium-binding agents for treating hypertension and hyperkalemia
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERKALEMIA
Ion binding polymers and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERKALEMIA
Methods and compositions for treatment of ion imbalances
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Ion binding polymers and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERKALEMIA
Ion binding polymers and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Ion binding polymers and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERKALEMIA
Linear polyol stabilized polyfluoroacrylate compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERKALEMIA
Ion binding polymers and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERKALEMIA
Ion binding polymers and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERKALEMIA
Ion binding polymers and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERKALEMIA
Potassium-binding agents for treating hypertension and hyperkalemia
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERKALEMIA
Potassium-binding agents for treating hypertension and hyperkalemia
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERKALEMIA
International Patents for VELTASSA
When does loss-of-exclusivity occur for VELTASSA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 09282721
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 0917853
Estimated Expiration: See Plans and Pricing
Canada
Patent: 35058
Estimated Expiration: See Plans and Pricing
China
Patent: 2202670
Estimated Expiration: See Plans and Pricing
Patent: 3919792
Estimated Expiration: See Plans and Pricing
Croatia
Patent: 0150955
Estimated Expiration: See Plans and Pricing
Patent: 0181961
Estimated Expiration: See Plans and Pricing
Cyprus
Patent: 16850
Estimated Expiration: See Plans and Pricing
Patent: 20930
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 65988
Estimated Expiration: See Plans and Pricing
Patent: 57286
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 65988
Estimated Expiration: See Plans and Pricing
Patent: 57286
Estimated Expiration: See Plans and Pricing
Patent: 31094
Estimated Expiration: See Plans and Pricing
Germany
Patent: 2009002063
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 84675
Estimated Expiration: See Plans and Pricing
Hungary
Patent: 25934
Estimated Expiration: See Plans and Pricing
Patent: 800004
Estimated Expiration: See Plans and Pricing
Patent: 900003
Estimated Expiration: See Plans and Pricing
Japan
Patent: 56403
Estimated Expiration: See Plans and Pricing
Patent: 83471
Estimated Expiration: See Plans and Pricing
Patent: 32468
Estimated Expiration: See Plans and Pricing
Patent: 33583
Estimated Expiration: See Plans and Pricing
Patent: 90116
Estimated Expiration: See Plans and Pricing
Patent: 12500806
Estimated Expiration: See Plans and Pricing
Patent: 14144977
Estimated Expiration: See Plans and Pricing
Patent: 14144978
Estimated Expiration: See Plans and Pricing
Patent: 16145256
Estimated Expiration: See Plans and Pricing
Patent: 17218454
Estimated Expiration: See Plans and Pricing
Patent: 19065030
Estimated Expiration: See Plans and Pricing
Patent: 20172537
Estimated Expiration: See Plans and Pricing
Lithuania
Patent: 957286
Estimated Expiration: See Plans and Pricing
Patent: 2018004
Estimated Expiration: See Plans and Pricing
Patent: 2018016
Estimated Expiration: See Plans and Pricing
Patent: 57286
Estimated Expiration: See Plans and Pricing
Luxembourg
Patent: 0094
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 4398
Estimated Expiration: See Plans and Pricing
Patent: 11001893
Estimated Expiration: See Plans and Pricing
Netherlands
Patent: 0962
Estimated Expiration: See Plans and Pricing
Norway
Patent: 18004
Estimated Expiration: See Plans and Pricing
Patent: 18041
Estimated Expiration: See Plans and Pricing
Poland
Patent: 65988
Estimated Expiration: See Plans and Pricing
Patent: 57286
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 65988
Estimated Expiration: See Plans and Pricing
Patent: 57286
Estimated Expiration: See Plans and Pricing
San Marino
Patent: 01500207
Estimated Expiration: See Plans and Pricing
Slovenia
Patent: 65988
Estimated Expiration: See Plans and Pricing
Patent: 57286
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 1825113
Estimated Expiration: See Plans and Pricing
Patent: 1928973
Estimated Expiration: See Plans and Pricing
Patent: 2150184
Estimated Expiration: See Plans and Pricing
Patent: 2178208
Estimated Expiration: See Plans and Pricing
Patent: 2300471
Estimated Expiration: See Plans and Pricing
Patent: 110063647
Estimated Expiration: See Plans and Pricing
Patent: 180014845
Estimated Expiration: See Plans and Pricing
Patent: 180133561
Estimated Expiration: See Plans and Pricing
Patent: 200029614
Estimated Expiration: See Plans and Pricing
Patent: 200128600
Estimated Expiration: See Plans and Pricing
Spain
Patent: 45887
Estimated Expiration: See Plans and Pricing
Patent: 99494
Estimated Expiration: See Plans and Pricing
United Kingdom
Patent: 75657
Estimated Expiration: See Plans and Pricing
Patent: 95426
Estimated Expiration: See Plans and Pricing
Patent: 95427
Estimated Expiration: See Plans and Pricing
Patent: 95428
Estimated Expiration: See Plans and Pricing
Patent: 1104561
Estimated Expiration: See Plans and Pricing
Patent: 1222749
Estimated Expiration: See Plans and Pricing
Patent: 1222750
Estimated Expiration: See Plans and Pricing
Patent: 1222752
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VELTASSA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2453048 | See Plans and Pricing | |
United Kingdom | 2456256 | POTASSIUM ION BINDING POLYMERS FOR PHARMACEUTICAL COMPOSITIONS | See Plans and Pricing |
Japan | 5756403 | See Plans and Pricing | |
Japan | 2020172537 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 (CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA) | See Plans and Pricing |
Japan | 2019065030 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 (CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA) | See Plans and Pricing |
Japan | 5883471 | See Plans and Pricing | |
Japan | 4974882 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VELTASSA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2957286 | CA 2018 00043 | Denmark | See Plans and Pricing | PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721 |
2957286 | 2018C/047 | Belgium | See Plans and Pricing | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
1732523 | 122018000011 | Germany | See Plans and Pricing | PRODUCT NAME: PATIROMER UND SALZE DAVON IN ALLEN VOM GRUNDPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/17/1179 20170719 |
2957286 | PA2018016,C2957286 | Lithuania | See Plans and Pricing | PRODUCT NAME: PATIROMERO, SORBITOLIO IR KALCIO KOMPLEKSAS; REGISTRATION NO/DATE: EU/1/17/1179 20170719 |
2957286 | 404 50019-2018 | Slovakia | See Plans and Pricing | PRODUCT NAME: PATIROMER SORBITEX KALCIUM; REGISTRATION NO/DATE: EU/1/17/1179/001 - EU/1/17/1179/009 20170721 |
2957286 | 122018000145 | Germany | See Plans and Pricing | PRODUCT NAME: PATIROMER SORBITEX CALCIUM IN ALLEN VOM GRUNDPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/17/1179 20170719 |
2365988 | LUC00061 | Luxembourg | See Plans and Pricing | PRODUCT NAME: PATIROMER SORBITEX CALCIUM ET TOUS LES SELS ET DERIVES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |